TriangleNivolumab, Fluorouracil, and… (NCT04380545)
Nivolumab, Fluorouracil, and Interferon Alpha 2B trial for Unresectable Fibrolamellar Carcinoma (NCT04380545). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Fibrolamellar carcinoma is a rare liver cancer that mostly affects adolescents and young adults, and few drug treatments have proven benefit.
The idea: add an immune-stimulating antibody to chemotherapy and interferon. Fluorouracil is given by vein and interferon alpha 2b by injection for two cycles. Then nivolumab, an antibody that may help the immune system attack the cancer, is added.
The first question is safety. The study then looks at how tumors respond, compared with earlier patients treated at the same hospital. At MD Anderson in Houston, Sunyoung Lee leads it, for cancer that cannot be removed by surgery.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.